Moleculin Biotech (NASDAQ:MBRX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
Volatility and Risk
Moleculin Biotech has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of -3.79, meaning that its share price is 479% less volatile than the S&P 500.
This table compares Moleculin Biotech and vTv Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Moleculin Biotech||N/A||N/A||-$11.88 million||($0.51)||-2.27|
|vTv Therapeutics||$12.43 million||6.44||-$7.91 million||($0.69)||-2.30|
vTv Therapeutics has higher revenue and earnings than Moleculin Biotech. vTv Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings for Moleculin Biotech and vTv Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Moleculin Biotech presently has a consensus price target of $5.50, suggesting a potential upside of 374.14%. vTv Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 88.68%. Given Moleculin Biotech’s higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than vTv Therapeutics.
Insider & Institutional Ownership
4.6% of Moleculin Biotech shares are held by institutional investors. Comparatively, 1.2% of vTv Therapeutics shares are held by institutional investors. 11.2% of Moleculin Biotech shares are held by company insiders. Comparatively, 1.7% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Moleculin Biotech and vTv Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Moleculin Biotech beats vTv Therapeutics on 8 of the 12 factors compared between the two stocks.
About Moleculin Biotech
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. It also engages in the preclinical development of other drug candidates, including other STAT3 inhibitors and compounds targeting the metabolism of tumors. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug; and the Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
About vTv Therapeutics
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.